Plasma metabolomic profiling to predict durable response and survival with afatinib in EGFR-mutated non-small cell lung cancer: A prospective, multicenter, observational biomarker study
While EGFR tyrosine kinase inhibitors (TKIs) like afatinib are standard treatments for EGFR-mutated non-small cell lung cancer (NSCLC), predicting which patients will achieve durable responses remains challenging. Given the emergence of more toxic and costly combination therapies, identifying candidates who can ach...